{
    "clinical_study": {
        "@rank": "58768", 
        "arm_group": {
            "arm_group_label": "Brentuximab vedotin", 
            "arm_group_type": "Experimental", 
            "description": "Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg."
        }, 
        "brief_summary": {
            "textblock": "This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy\n      and safety of brentuximab vedotin as a single agent in adult patients with histologically\n      confirmed CD30+ relapsed or refractory classical HL who have not received a prior stem cell\n      transplantation (SCT) and are considered to be not suitable for SCT or multiagent\n      chemotherapy at the time of study entry."
        }, 
        "brief_title": "A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Each patient must meet all of the following inclusion criteria to be enrolled in the\n        study:\n\n          1. Male or female patients 18 years or older, with relapsed or refractory classical HL,\n             who have previously received at least 1 prior systemic chemotherapeutic regimen\n\n          2. Not suitable for SCT or multiagent chemotherapy, according to 1 of the following\n             criteria:\n\n               -  Disease progression within 90 days of the earliest date of complete remission\n                  (CR) or complete remission unconfirmed (CRu) after the end of treatment with\n                  multiagent chemotherapeutic regimens and/or radiotherapy\n\n               -  Progressive disease during frontline multiagent chemotherapy\n\n               -  Disease relapse after treatment with at least 2 chemotherapeutic regimens,\n                  including any salvage treatments\n\n          3. Bidimensional measurable disease\n\n          4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\n          5. Female patients who are postmenopausal for at least 1 year before the screening\n             visit, surgically sterile, or agree to practice 2 effective methods of contraception\n             at the same time, or agree to practice true abstinence.\n\n          6. Male patients who agree to practice effective barrier contraception during the entire\n             study treatment period through 6 months after the last dose of study drug or agree to\n             practice true abstinence.\n\n          7. Clinical laboratory values as specified in the study protocol.\n\n        Exclusion Criteria\n\n        Patients who meet any of the following exclusion criteria are not to be enrolled in the\n        study:\n\n          1. Previous treatment with brentuximab vedotin\n\n          2. Previously received an ASCT or alloSCT\n\n          3. Known cerebral/meningeal disease, including signs or symptoms suggestive of\n             progressive multifocal leukoencephalopathy (PML), or any history of PML.\n\n          4. Female patients who are lactating and breastfeeding or pregnant.\n\n          5. Known human immunodeficiency virus (HIV).\n\n          6. Known hepatitis B surface antigen positive, or known or suspected active hepatitis C\n             infection.\n\n          7. Grade 2 or higher peripheral neuropathy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990534", 
            "org_study_id": "C25007", 
            "secondary_id": [
                "2013-000232-10", 
                "U1111-1154-2250"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Brentuximab vedotin", 
            "description": "Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.", 
            "intervention_name": "Brentuximab vedotin", 
            "intervention_type": "Drug", 
            "other_name": [
                "SGN-35", 
                "ADCETRIS"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lymphoma", 
            "Hodgkin", 
            "Relapsed", 
            "Refractory", 
            "Antigens, CD30", 
            "Antibody-Drug Conjugate", 
            "Antibodies, Monoclonal", 
            "Monomethyl auristatin E", 
            "Drug Therapy", 
            "Immunotherapy", 
            "Hematologic Diseases", 
            "Additional Relevant MeSH terms:", 
            "Lymphoma, Large B-Cell, Diffuse", 
            "Lymphoma, Hodgkin", 
            "Neoplasms by Histologic Type", 
            "Neoplasms", 
            "Lymphoproliferative Disorders", 
            "Lymphatic Diseases", 
            "Immunoproliferative Disorders", 
            "Immune System Diseases", 
            "Lymphoma, B-Cell", 
            "Lymphoma, T-Cell", 
            "Immunologic Factors", 
            "Physiological Effects of Drugs", 
            "Pharmacologic Actions"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic", 
                        "state": "Prague"
                    }, 
                    "name": "First Faculty of Medicine, Charles University in Prague"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia"
                    }, 
                    "name": "University Malaya Medical Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland"
                    }, 
                    "name": "Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "Malopolskie Centrum Medyczne S.C."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }, 
                    "name": "Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Clinic Barcelona"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain"
                    }, 
                    "name": "Complejo Hospitalario de Navarra"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Malaysia", 
                "Poland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate (ORR, complete remission (CR) + partial remission (PR)) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma", 
            "safety_issue": "No", 
            "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of response, PFS, CR rate, and duration of CR, by IRF assessment", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
            }, 
            {
                "measure": "Proportion of patients who receive SCT after treatment with brentuximab vedotin", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months for 18 months after end of treatment (EOT), thereafter, every 6 months until the sooner of death, study closure, or 5 years after enrollment of the last patient"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}